A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Phase 2

Terminated

Interventions: Drug: Ranibizumab
Drug: PF-04634817
Drug: Masked Sham Therapy
Drug: Placebo

Brief Summary: The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema. The current treatment option for these subjects is an injection directly into the eye, while this CCR2/5 antagonist would be an oral drug which has the potential to be just as effective. This CCR2/5 antagonist also has a broader anti-inflammatory potential and might be able to provide an alternative mechanism to treat Diabetic Macular Edema.

Detailed Description: Study recruitment was stopped on April 9, 2015. This decision was taken for business reasons due to changes in the prioritization of the drug development portfolio. This decision was not as a result of any evolving safety, efficacy issue or changes in the risk:benefit assessment of this product or regulatory interactions.

Recruitment & Eligibility

Inclusion Criteria

Patients with Diabetes Mellitus (Type 1 or Type 2) Showing Diabetic Macular Edema in the Eye
Reduced visual acuity resulting from retinal thickening
Female subjects of non-childbearing potential ≥18 years and male subjects greater than or equal to 18 years. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
Female subjects who are not of childbearing potential must meet at least one of the following criteria:
- Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- Have medically confirmed ovarian failure; or
- Achieved post-menopausal status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females.

Exclusion Criteria

Severe Impaired Renal Function
Any intraocular condition or previous surgery in either eye that would likely require medical or surgical intervention during the study duration or if allowed to progress untreated for the 16 weeks of study duration, would likely contribute to a reduction in visual acuity.

Arm && Interventions

Group	Intervention	Description
Arm 1	Ranibizumab	Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
Arm 2	Masked Sham Therapy	Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
Arm 1	Placebo	Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
Arm 2	PF-04634817	Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).

Primary Outcome Measures

Name	Time	Method
Mean Letter Change From Baseline at Week 12 in Best Corrected Visual Acuity (BCVA)	Baseline (Day 0) and Week 12	Refraction and visual acuity were assessed through the BCVA obtained using the retro illuminated early treatment diabetic retinopathy study (ETDRS) charts. Distance visual acuity was expressed as an ETDRS score (number of letters correctly read).

Secondary Outcome Measures

Name	Time	Method
Proportion of Subjects Gaining 15 ETDRS Letters in BCVA From Baseline at Week 12	Baseline (Day 0) and Week 12	Refraction and visual acuity were assessed through the BCVA obtained using the retro illuminated ETDRS charts. Distance visual acuity was expressed as an ETDRS score (number of letters correctly read).
Mean Change From Baseline in Central Subfield Retinal Thickness in the Study Eye at Week 12	Baseline (Day 0) and Week 12	A central reading center was used for the evaluation. A photographer or technician pre certified ("study certified") by the Central Reading Center ought to perform all optical coherence tomography (OCT) imaging. Use of a Spectralis or Cirrus OCT was acceptable.
Mean Change From Baseline in The Area of Fluorescein Leakage in the Study Eye at Week 12	Baseline (Day 0) and Week 12	Fluorescein Angiography (FA) using certified digital systems was taken by a photographer who had been pre-certified ("study-certified") by the Central Reading Center. They were evaluated by the Central Reading Center.
Mean Change From Baseline in Steps of Diabetic Retinopathy Step (ETDRS Severity Scale) in the Study Eye at Week 12	Baseline (Day 0) and Week 12	Stereo color fundus photographs using certified digital systems were taken by a photographer who had been pre-certified ("study certified") by the Central Reading Center. They were evaluated by the Central Reading Center.
Plasma Concentration of PF-04634817 up to Week 12	Week 0, Week 4, Week 8, and Week 12

Locations (63): Retina Research Institute, LLC
🇺🇸
Phoenix, Arizona, United States
Retinal Consultants of Arizona
🇺🇸
Phoenix, Arizona, United States
Sunny View Medical Center
🇺🇸
Phoenix, Arizona, United States
Premier Research Group Limited
🇺🇸
Phoenix, Arizona, United States
Retina Centers, P.C.
🇺🇸
Tucson, Arizona, United States
Retina Institute of California
🇺🇸
Arcadia, California, United States
Retina Vitreous Associates Medical Group
🇺🇸
Beverly Hills, California, United States
Retinal Diagnostic Center
🇺🇸
Campbell, California, United States
Retina Associates of Orange County
🇺🇸
Laguna Hills, California, United States
Southern California Desert Retina Consultants
🇺🇸
Palm Desert, California, United States
Scroll for more (53 remaining)
Retina Research Institute, LLC
🇺🇸Phoenix, Arizona, United States